Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.

BMC cancer - 14 Sept 2022

Martínez-Laperche C, Sanz-Villanueva L, Díaz Crespo F J, Muñiz P, Martín Rojas R, Carbonell D, Chicano M, Suárez-González J, Menárguez J, Kwon M, Diez Martín J L, Buño I, Bastos Oreiro M

Abstract excerpt

EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients' response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in EZH2 at diagnosis in tissue and ctDNA in patients with FL and to assess the patients' outcomes after receiving immunochemotherapy, depending on the EZH2 mutation status. Among the...

Topics

Join the communities discussing this publication.

Cyclophosphamide
Doxorubicin
Enhancer of Zeste Homolog 2 Protein
Lymphoma, Follicular
Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 36104682
DOI: 10.1186/s12885-022-10070-z
PMCID: PMC9476261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.PMID 36104682Read ↗

Comparative Analysis of the Clinicopathological Features of Follicular Lymphoma With and Without EZH2 Y646 Mutation.Semantic proximity Read ↗

EZH2 alterations in follicular lymphoma: biological and clinical correlations.Semantic proximity Read ↗

EZH2 mutations are frequent and represent an early event in follicular lymphoma.Semantic proximity Read ↗

Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.Semantic proximity Read ↗

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.Semantic proximity Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus BendamustineSemantic proximity Read ↗

[INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].Semantic proximity Read ↗

The follicular lymphoma epigenome regulates its microenvironment.Semantic proximity Read ↗

Treating lymphoma is now a bit EZ-er.Semantic proximity Read ↗

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.Semantic proximity Read ↗

Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.